Status: Not yet recruiting
Study to Evaluate the Effect of HT-4253 for the Prevention of Alzheimer's Disease in APOE4 Carriers
Primary Objectives: To demonstrate that HT-4253 improves the amyloid risk profile by transitioning biomarker-positive APOE4 carriers from a positive, high risk APS2 score to a negative, low risk APS2 score. Secondary Objectives: * To assess the effects of HT-4253 on tau related blood biomarker progression over the study period. * To assess the effects of HT-4253 on amyloid related blood biomarker progression over the study period. * To assess the safety and tolerability of HT-4253 in the UAE population.
Participants needed: 112
Trial details
Phase: Phase 2Age: 50-75Biological sex: AllType: InterventionalSponsor: Halia Therapeutics, Inc.Updated: Apr 17, 2026Locations: 1
Eligibility criteria
Participant must be 50-75 years of age, without previous AD diagnosis at the tim... [+12]
Any medical or neurological condition that in the opinion of the PI may be suppo... [+23]